drugset / Trial / NCT03708861
Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to describe pharmacokinetics of maraviroc (MVC) 300 mg and atazanavir/ritonavir (ATV/r) 200/100 mg QD in HIV-infected stable patients.
Timeline
- Start
- 2016-01
- Primary completion
- 2017-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 200 mg | — |
| Subject | Atazanavir | Other / unclassified | 300 mg | — |
| Subject | Maraviroc | Other / unclassified | 300 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |